NCT06649630View on ClinicalTrials.gov

A Study Looking at How Different Doses of Study Medicine (Inno8) Works in the Body of Healthy Men

PHASE1RecruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

September 23, 2024

Primary Completion Date

May 4, 2026

Study Completion Date

May 4, 2026

Conditions
Haemophilia A
Interventions
DRUG

NNC0442-0344 A

"SAD: NNC0442-0344 A will be administered intravenously.~MAD: NNC0442-0344 A will be administered orally.~SSD: NNC0442-0344 A will be administered subcutaneously."

DRUG

Placebo

"SAD: Placebo will be administered intravenously.~MAD: Placebo will be administered orally.~SSD: Placebo will be administered subcutaneously."

Trial Locations (2)

10117

RECRUITING

Charité - Campus Charité Mitte - Charité Research Organisation GmbH, Berlin

NOT_YET_RECRUITING

Charité Research Organisation GmbH, Berlin

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY